Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
在市场动荡和不确定时期，许多投资者转向产生股息的股票。这些公司通常拥有很高的自由现金流，并通过奖励股东来奖励股东 高额股息支付。
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy .
Benzinga的读者可以通过访问我们的分析师股票评级页面来查看分析师对他们最喜欢的股票的最新看法。交易者可以对Benzinga庞大的分析师评级数据库进行排序，包括 根据分析师的准确性 。
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
以下是最准确的分析师对医疗保健行业三只高收益股票的评级。
Pfizer Inc. (NYSE:PFE)
辉瑞公司（纽约证券交易所代码：PFE）
- Dividend Yield: 6.38%
- Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $45 on April 5, 2024. This analyst has an accuracy rate of 64%.
- Guggenheim analyst Vamil Divan initiated coverage on the stock with a Buy rating and a price target of $36 on Feb. 23, 2024. This analyst has an accuracy rate of 77%.
- Recent News: Pfizer recently released top-line immunogenicity and safety data from the ongoing pivotal Phase 3 MONeT trial,evaluating a single dose of Abrysvo versus placebo in adults 18 to 59 years of age at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD).
- 股息收益率：6.38%
- 坎托·菲茨杰拉德分析师路易丝·陈在2024年4月5日重申增持评级，目标股价为45美元。这位分析师的准确率为64％。
- 古根海姆分析师瓦米尔·迪万于2024年2月23日开始对该股进行报道，评级为买入，目标股价为36美元。这位分析师的准确率为77％。
- 最新消息：辉瑞最近发布了正在进行的关键性3期MoNet试验的主要免疫原性和安全性数据，该试验评估了18至59岁有患严重呼吸道合胞病毒（RSV）相关下呼吸道疾病（LRTD）风险的成年人单剂量的Abrysvo对比安慰剂。
GSK plc (NYSE:GSK)
葛兰素史克公司（纽约证券交易所代码：GSK）
- Dividend Yield: 3.61%
- BMO Capital analyst Etzer Darout maintained an Outperform rating and cut the price target from $82 to $80 on Feb. 12, 2024. This analyst has an accuracy rate of 60%.
- Morgan Stanley analyst Mark Purcell initiated coverage on the stock with an Overweight rating and a price target of $85 on Jan. 23, 2024. This analyst has an accuracy rate of 65%.
- Recent News: CureVac released interim data on Thursday, April 4, from studies it conducted on its seasonal influenza vaccine candidate. The study is part of a collaboration with GSK Plc.
- 股息收益率：3.61%
- BMO Capital分析师埃策·达鲁特维持跑赢大盘的评级，并于2024年2月12日将目标股价从82美元下调至80美元。这位分析师的准确率为60％。
- 摩根士丹利分析师马克·珀塞尔于2024年1月23日开始对该股进行报道，增持评级，目标股价为85美元。该分析师的准确率为65％。
- 最新消息：CureVac于4月4日星期四发布了针对其季节性流感候选疫苗的研究的中期数据。该研究是与葛兰素史克集团合作的一部分。
Patterson Companies, Inc. (NASDAQ:PDCO)
帕特森公司有限公司（纳斯达克股票代码：PDCO）
- Dividend Yield: 4.05%
- Morgan Stanley analyst Erin Wright maintained an Equal-Weight rating and slashed the price target from $38 to $35 on Nov. 30, 2023. This analyst has an accuracy rate of 78%.
- Stifel analyst Jonathan Block reiterated a Hold rating with a price target of $32 on Nov. 28, 2023. This analyst has an accuracy rate of 79%.
- Recent News: On March 11, Patterson Companies approved a $500 million stock buyback and declared a quarterly dividend of 26 cents per share.
- 股息收益率：4.05%
- 摩根士丹利分析师艾琳·赖特维持同等权重评级，并于2023年11月30日将目标股价从38美元下调至35美元。该分析师的准确率为78％。
- Stifel分析师乔纳森·布洛克在2023年11月28日重申了持有评级，目标股价为32美元。这位分析师的准确率为79％。
- 最新消息：3月11日，帕特森公司批准了5亿美元的股票回购，并宣布季度股息为每股26美分。
Read More: Jim Cramer Says WESCO International Is A Buy, Recommends Buying This Stock Under $20
阅读更多： 吉姆·克莱默说WESCO International值得买入，建议在20美元以下买入这只股票